Radiolabeled meta-iodobenzylguanidine: pharmacology and clinical studies
Sisson, J.C.; Wieland, D.M.
American Journal of Physiologic Imaging 1(2): 96-103
1986
ISSN/ISBN: 0885-8276 PMID: 3330445 Document Number: 4533
Much was known of the pharmacology of meta-iodobenzylguanidine (MIBG) before its clinical use, but we have since learned a good deal more about the metabolic distribution and fate of this radiopharmaceutical. And, as is the nature of science, more is yet to be discovered. This communication reviews what is known about the pharmacology of radiolabeled MIBG and how this pharmacology affects the clinical studies that use the agent.
Document emailed within 1 workday
Related Documents
Raes, M.; Coolens, J.L.; Van de Casseye, W.; Casteels-Van Daele, M.; De Roo, M. 1986: The use of 131I-meta-iodobenzylguanidine in clinical diagnosis and staging of neuroectodermal tumors. Two case reports Helvetica Paediatrica Acta 41(1-2): 63-67Troncone, L.; Rufini, V.; Campioni, P.; Valle, G.; Giordano, C.; Ala, G.; Deleide, G.; Orlando, P. 1985: Evaluation of a new adrenomedullary imaging agent: 131I-meta-iodobenzylguanidine (131I-MIBG). I: Experimental studies on animals Rays 10(2): 117-124
Samnick, S.; Kirsch, C.M. 1999: A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications Nuklearmedizin. Nuclear Medicine 38(7): 292-296
Villadsen, H.D.; Abrahamsen, J. 1997: Meta-iodobenzylguanidine scintigraphy of the heart Ugeskrift for Laeger 159(45): 6671-6675
Caballero, O.; Ferris, J.; Escobedo, J.M.; Pérez, A. 1989: Gammagraphy with 123I-meta-iodobenzylguanidine in the diagnosis of pheochromocytoma Medicina Clinica 92(14): 526-529
Fernández-Fresnedo, G.; Herráez, I.; Ruiz San Millán, J.C.; Sanz de Castro, S. 2000: False-negative with 123I-meta-iodobenzylguanidine in patients with pheochromocytoma Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 20(5): 464
Baulieu, J.L.; Guilloteau, D.; Fetissof, F.; Caron, J.; Lecomte, P.; Guilmot, J.L.; Lipinski, F.; Baulieu, F.; Itti, R.; Pourcelot, L. 1984: Sympathetic paraganglioma. Scintigraphic detection using a new labeled molecule, meta-iodobenzylguanidine Presse Medicale 13(27): 1679-1682
Troncone, L.; Rufini, V.; Maini, C.L.; Valenza, V.; Danza, F.M.; Lasorella, A. 1986: Possibility of using 131I-meta-iodobenzylguanidine in the diagnosis of neuroendocrine tumors differing from pheochromocytomas La Radiologia Medica 72(12): 963-968
Maurelli, L.; Cuocolo, A.; Lastoria, S.; Brunetti, A.; Maurea, S.; Lembo, G.; Klain, M.; Caracò, C.; Salvatore, M. 1991: 131I-meta-iodobenzylguanidine scintigraphy in patients with a suspected pheochromocytoma. a comparison with CT and biohumoral parameters La Radiologia Medica 82(6): 839-843
Kazuta, T.; Hayashi, M.; Yoshita, M.; Hirai, S. 1998: Iodine-123-labeled meta-iodobenzylguanidine myocardial scintigraphy evaluation of Machado-Joseph disease Rinsho Shinkeigaku 38(2): 97-101
Lumbroso, J.D.; Guermazi, F.; Hartmann, O.; Coornaert, S.; Rabarison, Y.; Leclère, J.G.; Couanet, D.; Bayle, C.; Caillaud, J.M.; Lemerle, J. 1988: Meta-iodobenzylguanidine (mIBG) scans in neuroblastoma: sensitivity and specificity, a review of 115 scans Progress in Clinical and Biological Research 271: 689-705
Goldenberg, D.M.; DeLand, F.H. 1984: Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase Urologic Clinics of North America 11(2): 277-281
Jindahra, P.; Vejjajiva, A.; Witoonpanich, R.; Sirisriro, R.; Sritara, C.; Pulkes, T. 2004: Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report) Journal of the Medical Association of Thailand 87(10): 1176-1181
Hirtz, J.; Le Roux, Y.; Jaouen, A.; Richard, J.; Blatrix, C.; Thébault, J.J.; Schoeller, J.P. 1979: Clinical pharmacology studies with acenocoumarol International Journal of Clinical Pharmacology and Biopharmacy 17(8): 361-365
Vyas, B. 2001: European Association of Clinical Pharmacology and Therapeutics--Fifth Congress. Clinical pharmacology: from molecule to society--bridging the gap via Man IDrugs: the investigational drugs journal 4(10): 1133-1137
Poulsen, H.Enghusen.; Schmitz, O.E.; Brøsen, K. 2002: Clinical pharmacology 2001--important events. The Danish Society of Clinical Pharmacology Ugeskrift for laeger 164(12): 1652
Farnier, M. 1992: The "duration of administration" factor in studies of clinical pharmacology of hypolipemic drugs Archives des Maladies du Coeur et des Vaisseaux 85(Special Issue 2): 113-115
Reid, T.S.; White, J.; Meneghini, L. 2019: The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care Journal of Family Practice 68(1 Suppl)
Pop, C.; Garabagiu, D.; Bărbulescu, B.; Daraban, D.; Schisser, G.; Schiopu, M.; Zabreanu, M.; Roşu, R.; Fanea, A.; Popa, A.; Vlaicu, R. 1999: The primary prevention of arterial hypertension. A meta-analysis of controlled clinical studies Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 103(1-2): 77-87
Gupta, P.P.; Tangri, A.N.; Saxena, R.C.; Dhawan, B.N. 1982: Clinical pharmacology studies on 4-N-butylamino-1,2,3,4-tetrahydroacridine hydrochloride (Centbucridine)--a new local anaesthetic agent Indian Journal of Experimental Biology 20(4): 344-346